Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel.
The ATP-binding cassette (ABC) superfamily of proteins comprises several ATP-dependent efflux pumps involved in transport of toxins and xenobiotics from cells. These transporters are essential components of normal physiology, and a subset is associated with development of multidrug resistance. P-glycoprotein (Pgp) and the multidrug resistance-associated proteins (MRPs) represent two classes of these multidrug resistance (MDR) transporters. MRP1 is one type of mammalian MRP, which preferentially transports anionic compounds and compounds detoxified by cellular enzymes such as glutathione-S-transferase. It also transports signaling molecules, including immunomodulators. In schistosomes, both Pgp and MRP substrates localize to the excretory system, a potentially attractive target for new antischistosomals. We have previously shown that expression of schistosome Pgp (SMDR2) is altered in worms exposed to praziquantel (PZQ), the current drug of choice against schistosomiasis, and is expressed at higher levels in worms from isolates with reduced PZQ susceptibility. We have also shown that PZQ interacts directly with SMDR2. Here, we examine the relationship between PZQ and SmMRP1, a Schistosoma mansoni homolog of mammalian MRP1. SmMRP1 RNA is differentially expressed in adult males and females, and levels increase transiently following exposure of adult worms to sub-lethal concentrations of PZQ. A corresponding, though delayed, increase in anti-MRP1-immunoreactive protein also occurs following exposure to PZQ. PZQ-insensitive juvenile worms express higher levels of both SmMRP1 and SMDR2 RNA than mature adults, consistent with the hypothesis that increases in levels of schistosome multidrug transporters may be involved in development or maintenance of reduced susceptibility to PZQ.
Kasinathan
Ravi S
RS
Department of Pathobiology, University of Pennsylvania, Philadelphia, 19104, USA.
Morgan
William M
WM
Greenberg
Robert M
RM
D000818:Animals; D000871:Anthelmintics / Q000378:metabolism*; D018432:Drug Resistance, Multiple; D005260:Female; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D015801:Helminth Proteins / Q000235:genetics / Q000378:metabolism*; D008297:Male; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics / Q000378:metabolism*; D011223:Praziquantel / Q000378:metabolism*; D012550:Schistosoma mansoni / Q000187:drug effects / Q000235:genetics / Q000254:growth & development / Q000378:metabolism*; D012555:Schistosomiasis mansoni / Q000469:parasitology
D000871:Anthelmintics; D015801:Helminth Proteins; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D011223:Praziquantel; C421109:multidrug resistance-associated protein 1
Mol Biochem Parasitol. 1994 Jun;65(2):351-6
7969275
Exp Parasitol. 1999 Mar;91(3):250-7
10072327
J Biol Chem. 1994 Nov 11;269(45):27807-10
7961706
Mol Cell Biochem. 2008 Oct;317(1-2):77-84
18543082
Biotechniques. 2002 Mar;32(3):536-8, 540
11911656
Chronic Illn. 2008 Mar;4(1):65-79
18322031
Toxicology. 2001 Oct 5;167(1):3-23
11557126
Trends Parasitol. 2009 Jul;25(7):328-35
19541539
Parasitology. 2006 Mar;132(Pt 3):321-30
16318676
Biochim Biophys Acta. 2008 Oct;1778(10):2413-20
18621020
J Biol Chem. 2007 May 11;282(19):14337-47
17374608
Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37
15845415
Parasitology. 2009 Aug;136(9):1081-8
19549355
Parasitology. 2004 Jan;128(Pt 1):43-52
15002903
Curr Opin Infect Dis. 2008 Dec;21(6):659-67
18978535
Mol Biochem Parasitol. 2009 Sep;167(1):54-9
19406169
Nat Med. 1997 Nov;3(11):1275-9
9359705
Int J Parasitol. 2004 Mar 29;34(4):527-33
15013742
Parasitol Res. 2003 Jun;90 Supp 1:S3-9
12811543
BMC Med. 2007 Sep 03;5:27
17767713
Int J Parasitol. 2005 Jan;35(1):1-9
15619510
Vet Parasitol. 2008 Mar 25;152(1-2):101-7
18241994
Curr Drug Targets. 2001 Mar;2(1):57-77
11465539
Acta Trop. 2003 May;86(2-3):125-39
12745133
Mol Biochem Parasitol. 2005 Sep;143(1):58-66
15993957
Trends Biochem Sci. 2000 Jan;25(1):1-6
10637601
Trends Parasitol. 2008 Jul;24(7):293-8
18514030
Trends Parasitol. 2009 Dec;25(12):538-9
19850522
Nat Protoc. 2008;3(6):1101-8
18546601
Int J Parasitol. 2005 Apr 30;35(5):555-66
15826647
Mol Biochem Parasitol. 1998 Mar 15;91(2):327-35
9566525
Mem Inst Oswaldo Cruz. 2006 Sep;101 Suppl 1:293-8
17308785
Exp Parasitol. 1986 Jun;61(3):294-303
3086114
PLoS Negl Trop Dis. 2009 Sep 29;3(9):e485
19787054
Z Parasitenkd. 1978 Jul 3;56(1):99-106
706553
Int J Antimicrob Agents. 2003 Sep;22(3):332-46
13678840
Science. 2009 Mar 27;323(5922):1718-22
19325113
Development. 2005 Jul;132(14):3197-207
15983401
Curr Drug Metab. 2008 Feb;9(2):167-74
18288958
Mol Biochem Parasitol. 1998 Sep 15;95(2):193-201
9803412
Bioorg Med Chem Lett. 2010 Apr 15;20(8):2481-4
20303754
Mol Biochem Parasitol. 2006 Jan;145(1):94-100
16257066
FASEB J. 2010 Jan;24(1):128-35
19726755
J Infect Dis. 1985 Jun;151(6):1130-7
3998507
Expert Rev Anti Infect Ther. 2006 Apr;4(2):199-210
16597202
Int Immunol. 2006 Mar;18(3):485-93
16481346
Bull World Health Organ. 2008 Oct;86(10):780-7, A
18949215
Oncogene. 2003 Oct 20;22(47):7468-85
14576852
J Clin Pharmacol. 2008 Mar;48(3):365-78
18156365
Pharmacol Ther. 1985;29(1):129-56
3914644
Mol Biochem Parasitol. 2009 Mar;164(1):57-65
19100294
Trends Immunol. 2009 Sep;30(9):421-9
19699682
Trends Parasitol. 2009 Aug;25(8):353-8
19617001
Parasitol Today. 1996 Jan;12(1):14-20
15275303
Cancer Res. 1994 Sep 1;54(17):4557-63
7914828